Previous close | 7.84 |
Open | 7.86 |
Bid | 8.08 x 400 |
Ask | 8.14 x 1200 |
Day's range | 7.68 - 8.14 |
52-week range | 4.54 - 16.75 |
Volume | |
Avg. volume | 6,332,733 |
Market cap | 1.929B |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.58 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.00 |
Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.
Recursion Pharmaceuticals (RXRX) closed at $7.47 in the latest trading session, marking a -1.32% move from the prior day.
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors Photo of Najat Khan, Ph.D. Najat Khan, Ph.D. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief